GlassScriptPhysician profile
Michael George Rashid
NPI 1992700975
$1,566.68
in general payments reported to CMS, 2019-2025
31 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $85.20 · 2022: $74.77 · 2023: $164 · 2024: $491 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $237.25 | 2023-2025 | Gemtesa, Orgovyx, Myfembree |
| Astellas Pharma US INC | $187.32 | 2019-2020 | |
| Abbvie INC. | $170.11 | 2020-2025 | |
| Procept Biorobotics Corporation | $151.68 | 2020-2024 | Aquabeam System |
| Immunitybio, INC. | $77.10 | 2024-2025 | |
| Convatec INC. | $72.26 | 2023-2024 | |
| Janssen Biotech, INC. | $62.30 | 2024-2025 | Erleada |
| Urogen Pharma, INC. | $60.50 | 2024-2025 | |
| Becton, Dickinson and Company | $45.12 | 2024 | Bard Urinary Drainage Bag |
| Tolmar, INC. | $43.19 | 2024-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $40.28 | 2019 | |
| Blue Earth Diagnostics | $38.66 | 2019-2025 | Posluma |
| Teleflex LLC | $31.60 | 2023-2025 | Barrigel, Urolift |
| Valencia Technologies Corporation | $30.39 | 2025 | Ecoin Device Kit |
| Bayer Healthcare Pharmaceuticals INC. | $28.40 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edap Technomed INC | $27.98 | 2025 | |
| Dendreon Pharmaceuticals LLC | $27.35 | 2019 | |
| Integra Lifesciences Corporation | $25.00 | 2022 | |
| Pfizer INC. | $24.54 | 2019 | |
| Antares Pharma, INC. | $24.19 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.12 | 2024 | Personal Catheter Intermittent Catheter |
| Progenics Pharmaceuticals, INC. | $21.00 | 2023 | Pylarify |
| Coloplast Corp | $17.45 | 2020 | |
| Endo USA, INC. | $16.33 | 2025 | Xiaflex |
| Halozyme INC | $15.88 | 2023 | |
| Amgen INC. | $13.75 | 2024 | Prolia |
| Medtronic, INC. | $13.72 | 2023 | Swiftset |
| Myriad Genetic Laboratories, INC. | $13.63 | 2025 | Prolaris |
| Urovant Sciences INC | $12.83 | 2022 | |
| Myovant Sciences INC. | $12.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.